J&J plans late-stage trial for lupus candidate after Phase 2 successnews2026-01-06T19:11:01+00:00January 6th, 2026|Endpoints News|
Bright Minds’ shares soar on positive Phase 2 seizure reduction datanews2026-01-06T16:33:16+00:00January 6th, 2026|Endpoints News|
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approvalnews2026-01-06T16:22:38+00:00January 6th, 2026|Endpoints News|
Amgen to acquire Dark Blue Therapeutics for up to $840Mnews2026-01-06T15:49:45+00:00January 6th, 2026|Endpoints News|
Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early datanews2026-01-06T12:30:29+00:00January 6th, 2026|Endpoints News|
Zenas BioPharma’s Phase 3 autoimmune disease readout disappointsnews2026-01-05T16:21:59+00:00January 5th, 2026|Endpoints News|
Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blockernews2025-12-30T15:17:17+00:00December 30th, 2025|Endpoints News|
Nido Bio to wind down after underwhelming Phase 2 datanews2025-12-29T17:23:00+00:00December 29th, 2025|Endpoints News|
Ultragenyx, Mereo crash on late-stage bone disease failurenews2025-12-29T15:37:52+00:00December 29th, 2025|Endpoints News|
Genmab terminates Phase 3 lung cancer asset that BioNTech ditchednews2025-12-29T15:17:58+00:00December 29th, 2025|Endpoints News|
